(64)Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts

Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent clinically used for various cancers. However, repeated use of this agent leads to tumor-decreased vascularity and hypoxia with activation of an HIF-1 signaling pathway, which results in drug delivery...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshii, Yukie, Yoshimoto, Mitsuyoshi, Matsumoto, Hiroki, Furukawa, Takako, Zhang, Ming-Rong, Inubushi, Masayuki, Tsuji, Atsushi B., Fujibayashi, Yasuhisa, Higashi, Tatsuya, Saga, Tsuneo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687648/
https://www.ncbi.nlm.nih.gov/pubmed/29179478
http://dx.doi.org/10.18632/oncotarget.21323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687648/
https://www.ncbi.nlm.nih.gov/pubmed/29179478
http://dx.doi.org/10.18632/oncotarget.21323

Ejemplares similares